A HPLC-Q-TOF-MS-based urinary metabolomic approach to identification of potential biomarkers of metabolic syndrome

Abstract

Metabolic syndrome (MetS) is a serious threat to public health worldwide with an increased risk of developing type 2 diabetes, cardiovascular diseases and all-cause morbidity and mortality. In this study, a urinary metabolomic approach was performed on high performance liquid chromatography quadrupole time-of-flight mass spectrometry to discriminate 36 male MetS patients and 36 sex and age matched healthy controls. Pattern recognition analyses (principal component analysis and orthogonal projections to latent structures discriminate analysis) commonly demonstrated the difference between MetS patients and no-MetS subjects. This study found 8 metabolites that showed significant changes in patients with MetS, including branch-chain and aromatic amino acids (leucine, tyrosine, phenylalanine and tryptophan), short-chain acylcanitine (tiglylcarnitine), tricarboxylic acid (TCA) cycle intermediate (cis-aconitic acid) and glucuronidated products (cortolone-3-glucuronide and tetrahydroaldosterone-3-glucuronide). The candidate biomarkers revealed in this study could be useful in providing clues for further research focusing on the in-depth investigation of the cause of and cure for MetS.

Keywords

metabolic syndrome / metabolomics / HPLC-Q-TOF-MS / urine / biomarker

References

[1] AlbertiKG, ZimmetP, ShawJ. The metabolic syndrome—a new worldwide definition. Lancet, 2005, 366(9491): 1059-1062

[2] AlbertiKG, EckelRH, GrundySM, et al.. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009, 120(16): 1640-1645

[3] GuD, ReynoldsK, WuX, et al.. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet, 2005, 365(9468): 1398-1405

[4] GamiAS, WittBJ, HowardDE, et al.. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 2007, 49(4): 403-414

[5] KahnR, BuseJ, FerranniniE, et al.. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005, 28(9): 2289-2304

[6] EckelRH, AlbertiKG, GrundySM, et al.. The metabolic syndrome. Lancet, 2010, 375(9710): 181-183

[7] KadowakiT, YamauchiT, KubotaN, et al.. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006, 116(7): 1784-1792

[8] EsteghamatiA, ZandiehA, ZandiehB, et al.. Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Endocrine, 2011, 40(1): 117-123

[9] TimpsonNJ, LawlorDA, HarbordRM, et al.. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet, 2005, 366(9501): 1954-1959

[10] NicholsonJK, WilsonID. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov, 2003, 2(8): 668-676

[11] RaamsdonkLM, TeusinkB, BroadhurstD, et al.. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol, 2001, 19(1): 45-50

[12] AnJ, MuoioDM, ShiotaM, et al.. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med, 2004, 10(3): 268-274

[13] OngES, ZouL, LiS, et al.. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics, 2010

[14] WangTJ, LarsonMG, VasanRS, et al.. Metabolite profiles and the risk of developing diabetes. Nat Med, 2011, 17(4): 448-453

[15] LvH, HungCS, ChaturvediKS, et al.. Development of an integrated metabolomic profiling approach for infectious diseases research. Analyst, 2011, 136(22): 4752-4763

[16] OthmanA, RuttiMF, ErnstD, et al.. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?. Diabetologia, 2012, 55(2): 421-431

[17] ZhangT, WuX, KeC, et al.. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res, 2013, 12(1): 505-512

[18] DunnWB, WilsonID, NichollsAW, et al.. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis, 2012, 4(18): 2249-2264

[19] BijlsmaS, BobeldijkI, VerheijER, et al.. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem, 2006, 78(2): 567-574

[20] AnZ, ChenY, ZhangR, et al.. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res, 2010, 9(8): 4071-4081

[21] ZhuZ, WangH, ShangQ, et al.. Time course analysis of candida albicans metabolites during biofilm development. J Proteome Res, 2013, 12(6): 2375-2385

[22] ZhangF, JiaZ, GaoP, et al.. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta, 2009, 79(3): 836-844

[23] WurtzP, TiainenM, MakinenVP, et al.. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care, 2012, 35(8): 1749-1756

[24] WurtzP, SoininenP, KangasAJ, et al.. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care, 2013, 36(3): 648-655

[25] PattiM E, BrambillaE, LuziL, et al.. Bidirectional modulation of insulin action by amino acids. J Clin Invest, 1998, 101(7): 1519-1529

[26] NewgardCB, AnJ, BainJR, et al.. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab, 2009, 9(4): 311-326

[27] Soares-da-SilvaP, Vieira-CoelhoMA, Pinto-doOP, et al.. Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens Res, 1995, 18(Suppl1): S47-S51

[28] HiroseM, TomodaF, KoikeT, et al.. Imbalance of renal production between 5-hydroxytryptamine and dopamine in patients with essential hypertension complicated by microalbuminuria. Am J Hypertens, 2013, 26(2): 227-233

[29] AdamsS H. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr, 2011, 2(6): 445-456

[30] MihalikSJ, GoodpasterBH, KelleyDE, et al.. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring), 2010, 18(9): 1695-1700

[31] SchoonemanMG, VazFM, HoutenSM, et al.. Acylcarnitines: reflecting or inflicting insulin resistance?. Diabetes, 2013, 62(1): 1-8

[32] SharmaS, SudN, WisemanDA, et al.. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2008, 294(1): L46-56

[33] SatapatiS, SunnyN E, KucejovaB, et al.. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res, 2012, 53(6): 1080-1092

[34] CusiK. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis, 2009, 13(4): 545-563

[35] CataniaVA, CarrilloMC. Intestinal phase II detoxification systems: effect of low-protein diet in weanling rats. Toxicol Lett, 1990, 54(2–3): 263-270

[36] XuJ, KulkarniSR, LiL, et al.. UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis. Drug Metab Dispos, 2012, 40(2): 259-266

[37] GuanHP, GoldsteinJL, BrownMS, et al.. Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL/J mice. J Biol Chem, 2009, 284(36): 24644-24652

[38] OsabeM, SugataniJ, FukuyamaT, et al.. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos, 2008, 36(2): 294-302